Attached files

file filename
EX-32.1 - EXHIBIT 32.1 - Symmetry Medical Inc.v309750_ex32-1.htm
EX-31.1 - EXHIBIT 31.1 - Symmetry Medical Inc.v309750_ex31-1.htm
EX-31.2 - EXHIBIT 31.2 - Symmetry Medical Inc.v309750_ex31-2.htm

UNITED STATES

 

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

  

FORM 10-K/A

  

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Fiscal Year Ended December 31, 2011

 

Commission File Number 001-32374

  

 

SYMMETRY MEDICAL INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware   35-1996126
(State of Incorporation)  

(I.R.S. Employer 

Identification No.)

 

3724 North State Road 15

 Warsaw, Indiana 46582

(Address of Principal Executive Offices) (Zip Code)

 

(574) 268-2252

(Registrant's Telephone Number, Including Area Code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class:   Name of Each Exchange on Which Registered:
Common Stock, Par Value $0.001 Per Share   New York Stock Exchange

 

Securities registered pursuant to section 12(g) of the Act: None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.Yes o No x

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.Yes o No x

 

Indicate by check mark whether the registrant (l) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of l934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.Yes x No o

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (S232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).Yes x No o

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. x

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and" smaller reporting company" in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer o   Accelerated filer x   Non-accelerated filer o   Smaller reporting company o

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).Yes o No x

 

The aggregate market value of voting stock of Symmetry Medical Inc. held by non-affiliates of the Registrant as of July 2, 2011, based on the closing price was $9.26, as reported by the New York Stock Exchange: Approximately $336.0 million.

 

The number of outstanding shares of the registrant's common stock as of March 12, 2012 was 36,575,331.

 
 

 

 

EXPLANATORY NOTE

 

This Form 10-K/A is being filed to correct a typographical error on the cover page of the original Form 10-K. The actual number of outstanding shares of the registrant's common stock as of March 12, 2012 was 36,575,331. As a result of a typographical error, the original Form 10-K erroneously listed this figure as 35,575,331. No other changes to the disclosure in the original Form 10-K are made by this Form 10-K/A.

 

 

 

 

 

 
 

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    SYMMETRY MEDICAL INC.
     
April 16, 2012  

By: /s/ Thomas J. Sullivan

       Thomas J. Sullivan

       Chief Executive Officer and President

     

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the date indicated.

 

Name   Title   Date

/s/ Thomas J. Sullivan

Thomas J. Sullivan

 

Chief Executive Officer, President and

 Director (Principal Executive Officer)

  April 16, 2012

 

 

/s/ Fred L. Hite

Fred L. Hite

 

Senior Vice President,

 

Chief Financial Officer and Secretary

 

 

 

April 16, 2012

 

/s/ Ronda L. Harris

Ronda L. Harris

 

 

Chief Accounting Officer

 

 

April 16, 2012

 

*         Craig B. Reynolds

 

 

Director

 

 

April 16, 2012

 

*         Francis T. Nusspickel

 

 

Director

 

 

April 16, 2012

 

*         James S. Burns

 

 

Director

 

 

April 16, 2012

 

*         John S. Krelle

 

 

Director

 

 

April 16, 2012

 

*         Thomas E. Chorman

 

 

Director

 

 

April 16, 2012

 

*         Robert G. Deuster

 

 

Director

 

 

April 16, 2012

         

*By: /s/ Fred L. Hite

 Fred L. Hite

 Attorney-in-fact

 Pursuant to Power of Attorney

 (Exhibit 24.1 hereto)